A research team at Yale School of Medicine successfully treated a person with disfiguring sarcoidosis with Xeljanz (tofacitinib) — an existing approved treatment against rheumatoid arthritis — resulting in a near-complete disappearance of skin lesions. The findings were published in the New England Journal of Medicine in an…
News
Middle-aged adults with impaired lung function, such as people with sarcoidosis, are at higher risk of dementia and mild cognitive impairment, according to a long-term follow-up study. The study, “Impaired Lung Function, Lung Disease and Risk of Incident Dementia” was published in the American Journal of…
Better quality of life and greater functionality are the most important treatment goals for people with sarcoidosis, according to a large-scale survey of patient perspectives. Survey results are expected to be included in European Respiratory Society (ERS) guidelines to be released this year. They were reported in “…
Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…
After the U.S. Food and Drug Administration accepted aTyr Pharma‘s investigational new drug application for ATYR1923, the company announced it will initiate a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis. The company will collaborate with the Foundation for Sarcoidosis Research (FSR) for the…
News
Lymphopaenia a Noninvasive and Useful Biomarker for Diagnosing Ocular Sarcoidosis, Study Suggests
Low levels of white blood cells in the blood — a condition known as lymphopaenia — could be a useful, noninvasive biomarker for the diagnosis of ocular sarcoidosis, a study reports. The study, “Lymphopaenia as a predictor of sarcoidosis in patients with a first episode of uveitis,”…
More studies describing symptoms and disease severity in people with sarcoidosis and psoriasis are urgently needed to understand how the diseases may increase the risk of other medical conditions, a cross-sectional study says. “Examining the epidemiology of coincident psoriasis and sarcoidosis: An observational cross-sectional study,” was published in the…
Researchers have reported a new case of cutaneous sarcoidosis in a Finnish woman previously treated for Hodgkin’s lymphoma — a type of blood cancer — noting that sarcoidosis development after lymphoma may be underreported. These insights were highlighted in a correspondence titled “Cutaneous sarcoidosis after Hodgkin…
Treatment with Rituxan (rituximab) provided marked disease remission and was well-tolerated by three patients with refractory neurosarcoidosis, according to a new case report. The study, “Successful therapy with rituximab in three patients with probable neurosarcoidosis,” was published in the journal Therapeutic Advances in Neurological…
Adalimumab — marketed by (Abbvie) as Humira — can help treat patients with verrucous sarcoidosis — a rare type of cutaneous (skin) sarcoidosis — associated with human papillomavirus (HPV) infection, according to a new case report. The study, “Chronic verrucous sarcoidosis associated with human papillomavirus infection:…
Recent Posts
- Autoimmune diseases tied to higher sarcoidosis risk, new study finds
- Atyr to discuss efzofitimod’s future with FDA after Phase 3 sarcoidosis trial
- How do you celebrate Autoimmune Awareness Month?
- New congressional caucus to advocate for sarcoidosis research, funding
- Free virtual conference aims to empower sarcoidosis community
- The best advice I ever got for dealing with a rare disease
- Sarcoidosis and ILD burden rising globally, new analysis finds
- At high dose, brepocitinib eases symptoms of sarcoidosis affecting skin
- Patients and healthcare providers should approach AI with caution
- New AI model predicts sudden cardiac death risk better in cardiac sarcoidosis